Spike (BA.1.1, Omicron Variant R346K) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
7015 EUR
In Stock
quantity
Produktdetaljer
Katalognummer: 421 - 78623-2
Produktkategori: Företag och industri > Vetenskap och laboratorium
Gentaur
Storlek: 500 µl x 2
Parameters
| Additional information | Applications: Screen for or titrate neutralizing antibodies against SARS-CoV-2 Spike BA.1.1 variant in ACE2-HEK293 cells.; |
|---|---|
| Storage and shipping | Shipping conditions: -80°C; Storage conditions: Lentiviruses are shipped with dry ice. For long-term storage, it is recommended to store the lentiviruses at -80°C for up to 12 months from date of receipt. Avoid repeated freeze/thaw cycles. Titers can drop significantly with each freeze/thaw cycle.; |
| Storage and shipping | With |
78623-1
Spike (BA.1.1, Omicron Variant R346K) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.1.529 BA.1 (also known as the Omicron Variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. A sub-lineage of BA.1 with an R346K substitution in the spike protein is classified as B.1.1.529 BA.1.1.The Spike (B.1.1.529 BA.1.1, Omicron Variant R346K) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.1.529 BA.1.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.1.529 BA.1.1 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.1.529 BA.1.1, Omicron Variant R346K Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 B.1.1.529 BA.1.1 variant in a Biosafety Level 2 facility.The Spike B.1.1.529 BA.1.1 pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).Spike Mutations in B.1.1.529 BA.1.1 Omicron Variant R346K:A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211, L212I, ins214EPE, G339D, R346K, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F
1500 €
78625-1
Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. The Omicron Variant (B.1.1.529 variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of February 2022, Omicron variants have been divided into four distinct sub-lineages: BA.1, BA.1.1, BA.2, and BA.3.The Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.2 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.2, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BA.2 variant in a Biosafety Level 2 facility.The Spike Omicron BA.2 pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).Spike Mutations in BA.2, Omicron Variant: T19I, LPPA24-27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K
1500 €
78625-2
Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. The Omicron Variant (B.1.1.529 variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of February 2022, Omicron variants have been divided into four distinct sub-lineages: BA.1, BA.1.1, BA.2, and BA.3.The Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.2 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.2, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BA.2 variant in a Biosafety Level 2 facility.The Spike Omicron BA.2 pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).Spike Mutations in BA.2, Omicron Variant: T19I, LPPA24-27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K
6915 €
78736-2
Spike (XBB.1.5, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter)
The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and human ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants were divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5. As of January 2023, additional new sub-lineages (e.g. BQ.1, BQ.1.1, BF.7, XBB.1, XBB.1.5) have been designated._x000D_The Spike (XBB.1.5, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the XBB.1.5 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter (Figure 1), therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (XBB.1.5, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron XBB.1.5 variant in a Biosafety Level 2 facility._x000D_<p style="text-align: center;"><img src="{{media url="wysiwyg/coronavirus/78736.png"}}" alt="" width="307" height="236" />_x000D_Figure 1. Schematic of the Luciferase Reporter in SARS-CoV-2 Spike Pseudovirion._x000D_As shown in Figure 2, the Spike Omicron XBB.1.5 pseudovirus has been validated for use with ACE2-HEK293 target cells (which overexpress ACE2; BPS Bioscience #79951)._x000D_Spike Mutations in XBB.1.5 Omicron Variant: T19I, LPP24-26del, A27S, V83A, G142D, Y144del, H146Q, Q183E, V213E, G252V, G339H, R346T, L368I, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, V445P, G446S, N460K, S477N, T478K, E484A, F486P, F490S, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K
6757.5 €
78784-1
Spike (XBB.1.16, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter)
The Spike (XBB.1.16, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses are replication incompetent, HIV-based lentiviral particles. They were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the XBB.1.16 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain firefly luciferase driven by a CMV promoter (Figure 1), allowing the spike-mediated cell entry to be measured by luciferase activity. The Spike (XBB.1.16, Omicron Variant) (SARS-CoV-2) pseudoviruses can be used to measure the activity of a neutralizing antibody against the SARS-CoV-2 Omicron XBB.1.16 variant.The Spike Omicron XBB.1.16 pseudoviruses have been validated for use with ACE2-HEK293 target cells (which overexpress ACE2; BPS Bioscience #79951) .Figure 1. Schematic of the lenti-vector used to generate the Luciferase Reporter in theSpike (XBB.1.16, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus.
Ask for quotation
78784-2
Spike (XBB.1.16, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter)
The Spike (XBB.1.16, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses are replication incompetent, HIV-based lentiviral particles. They were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the XBB.1.16 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain firefly luciferase driven by a CMV promoter (Figure 1), allowing the spike-mediated cell entry to be measured by luciferase activity. The Spike (XBB.1.16, Omicron Variant) (SARS-CoV-2) pseudoviruses can be used to measure the activity of a neutralizing antibody against the SARS-CoV-2 Omicron XBB.1.16 variant.The Spike Omicron XBB.1.16 pseudoviruses have been validated for use with ACE2-HEK293 target cells (which overexpress ACE2; BPS Bioscience #79951) .Figure 1. Schematic of the lenti-vector used to generate the Luciferase Reporter in theSpike (XBB.1.16, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus.
Ask for quotation
Håll dig uppdaterad! Visa tidigare publikationer
By: Author , 2 Comment
Katalas – ett extraordinärt enzym
30 January 2026
By: Author , 2 Comment
Anaplasmos hos hundar och katter – allt du behöver veta
23 August 2025
By: Author , 2 Comment
Solbränna – hur leker man säkert i solen?
16 August 2025
By: Author , 2 Comment
Biologiska läkemedel – Modernitet inom farmaci
1 August 2025